Table 5 Visual acuity and central retinal thickness outcome by response to ranibizumab and genotypes

ARMS2 rs10490924

GG (n = 16)

GT (n = 22)

TT (n = 16)

P ^c

GG (n = 5)

GT (n = 35)

TT (n = 51)

P ^c

 Age

66.68 ± 7.88

68.77 ± 6.97

69.38 ± 3.70

0.469

65.80 ± 5.81

71.34 ± 8.12

68.71 ± 8.07

0.187

 Smoking

5 (31.3)

8 (36.4)

2 (12.5)

0.251

2 (40.0)

16 (45.7)

17 (33.3)

0.509

 Mean BCVA (logMAR)^a

Baseline

0.58 ± 0.27

0.67 ± 0.27

0.72 ± 0.28

0.328^b

0.64 ± 0.35

0.49 ± 0.26

0.51 ± 0.22

0.509^b

3 months

0.51 ± 0.25

0.54 ± 0.27

0.67 ± 0.36

0.253

0.82 ± 0.26

0.61 ± 0.25

0.59 ± 0.23

0.191^b

6 months

0.33 ± 0.19

0.48 ± 0.26

0.45 ± 0.22

0.119^b

0.82 ± 0.26

0.65 ± 0.28

0.67 ± 0.28

0.420^b

 Mean CRT (μM)^a

Baseline

432.7 ± 107.73

490.5 ± 159.19

514.1 ± 180.79

0.307

370.2 ± 192.43

324.7 ± 86.96

324.1 ± 73.19

0.525

3 months

327.1 ± 88.53

367.3 ± 138.55

342.5 ± 103.94

0.562

397.8 ± 320.3

347.8 ± 128.34

357.1 ± 90.37

0.406^b

6 months

307.7 ± 85.37

323.6 ± 103.78

332.3 ± 108.36

0.78

374.4 ± 269.59

348.7 ± 143.92

421.4 ± 127.03

0.072

 Changes in BCVA (logMAR)^a

3 months

− 0.07 ± 0.13

− 0.13 ± 0.22

− 0.05 ± 0.23

0.462^b

0.18 ± 0.30

0.12 ± 0.21

0.08 ± 0.17

0.651^b

6 months

− 0.24 ± 0.16

− 0.19 ± 0.24

− 0.26 ± 0.23

0.593

0.18 ± 0.30

0.16 ± 0.21

0.15 ± 0.24

0.960^b

 Changes in CRT (μM)^a

3 months

− 105.6 ± 59.04

− 123.2 ± 122.81

− 171.6 ± 188.21

0.349

27.6 ± 136.82

23.1 ± 92.01

33.0 ± 72.25

0.865

6 months

− 125.0 ± 52.98

− 166.8 ± 135.36

− 181.8 ± 176.76

0.454

4.2 ± 85.65

23.9 ± 94.53

97.3 ± 128.36

0.009*

 Logistic regression^d

HTRA1 rs11200638

GG (n = 15)

GA (n = 21)

AA (n = 18)

GG (n = 4)

GA (n = 26)

AA (n = 61)

 Age

66.53 ± 8.13

68.95 ± 7.07

69.11 ± 3.66

0.455

63.75 ± 4.11

70.62 ± 8.39

69.49 ± 8.04

0.286

 Smoking

4 (26.7)

9 (42.9)

2 (11.1)

0.087

2 (50.0)

13 (50.0)

20 (32.8)

0.284

 Mean BCVA (logMAR)^a

Baseline

0.55 ± 0.25

0.69 ± 0.28

0.69 ± 0.27

0.192^b

0.73 ± 0.34

0.55 ± 0.26

0.48 ± 0.22

0.180^b

3 months

0.49 ± 0.25

0.58 ± 0.29

0.62 ± 0.33

0.521

0.90 ± 0.20

0.63 ± 0.25

0.58 ± 0.23

0.034^b*

6 months

0.32 ± 0.19

0.48 ± 0.26

0.46 ± 0.22

0.059^b

0.90 ± 0.20

0.67 ± 0.25

0.65 ± 0.29

0.191^b

 Mean CRT (μM)^a

Baseline

444.7 ± 99.74

487.1 ± 168.15

502.1 ± 174.90

0.556

382.0 ± 220.09

318.8 ± 80.19

326.7 ± 77.79

0.406

3 months

332.4 ± 88.99

380.5 ± 141.31

323.2 ± 94.33

0.251

417.5 ± 366.34

339.7 ± 116.68

358.6 ± 102.01

0.519^b

6 months

313.4 ± 85.14

333.1 ± 109.14

314.6 ± 100.66

0.794

388.3 ± 309.23

348.7 ± 146.94

408.9 ± 130.38

0.212

 Changes in BCVA (logMAR)^a

3 months

− 0.05 ± 0.10

− 0.12 ± 0.23

− 0.08 ± 0.23

0.735^b

0.18 ± 0.36

0.08 ± 0.20

0.10 ± 0.18

0.870^b

6 months

− 0.23 ± 0.16

− 0.22 ± 0.25

− 0.24 ± 0.22

0.945

0.18 ± 0.35

0.12 ± 0.18

0.17 ± 0.24

0.664^b

 Changes in CRT (μM)^a

3 months

− 112.3 ± 54.30

− 106.6 ± 115.37

− 178.9 ± 183.41

0.191

35.5 ± 156.67

20.9 ± 73.19

31.9 ± 83.25

0.846

6 months

− 131.3 ± 48.17

− 154.0 ± 135.01

− 187.5 ± 171.50

0.474

6.3 ± 98.75

29.9 ± 91.8

82.3 ± 128.03

0.107

 Logistic regression^d